KP Biomedical Engineering - Issue #24

-AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results MASON, Ohio--(BUSINESS WIRE)

--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced fourth quarter 2024 and full year 2024 financial results.

-QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results SAN DIEGO--(BUSINESS WIRE)

--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced financial results for the fourth quarter and full-year ended December 29, 2024.

-CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies BRISBANE, Calif.--(BUSINESS WIRE)

--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company? – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers announced new AlloHeme data presented at the 2025 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT? and CIBMTR?, held February 12-15, 2025 in Honolulu, Hawaii.

-MultiCare Connected Care Taps Tuva Health to Optimize the Data of its 375,000+ Patients SALT LAKE CITY--(BUSINESS WIRE)

--Tuva Health, the world's first open-source healthcare data transformation platform, announced it has partnered with MultiCare Connected Care (MCC), MultiCare Health System’s accountable care organization, to build, operate, and manage MCC’s enterprise healthcare data platform. In addition, MultiCare Capital Partners, the strategic investment arm of MultiCare, has invested in Tuva Health to further support the development of its open-source data model.

-Prenuvo Announces it Had Raised $120M to Advance Preventative Health, Launches Novel FDA-Cleared AI-Powered Products REDWOOD CITY, Calif.--(BUSINESS WIRE)

--Prenuvo, the leader in proactive whole-body MRI screening, disclosed that it quietly raised $120M as part of Series B fundraising during 2024, demonstrating its category leadership in preventative health. The company has identified over 1.4 million personalized health insights across its member base, highlighting the critical role of early detection.

-WhiteSwell Announces New Data Supporting Acute Decompensated Heart Failure Treatment with eLym System GALWAY, Ireland--(BUSINESS WIRE)

--WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced positive data from 21 patients treated in its DELTA-HF trial evaluating the WhiteSwell eLym? System. The data were presented at the Technology and Heart Failure Therapeutics (THT) meeting in Boston by Jan Biegus, M.D., deputy scientific director at the Institute of Heart Diseases at Wroclaw Medical University in Poland.

-Allurion Relaunches in France NATICK, Mass.--(BUSINESS WIRE)

--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales. “We are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.

-Evolus Announces FDA Approval of Evolysse? Form and Evolysse? Smooth Injectable Hyaluronic Acid Gels NEWPORT BEACH, Calif.--(BUSINESS WIRE)

--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse? Form and Evolysse? Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse? collection.

-Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies HERCULES, Calif.--(BUSINESS WIRE)

--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (“Stilla”).

-Covalon Announces Conference Call to Discuss First Quarter Fiscal 2025 Financial Results MISSISSAUGA, Ontario--(BUSINESS WIRE)

--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2025 financial results on Friday, February 21, 2025, before markets open. A conference call and webcast to discuss the financial results will be held on Friday, February 21, 2025, at 8:30am ET.

-New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX?Medical CAMBRIDGE, England--(BUSINESS WIRE)

--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients. The test identifies the presence or absence of cancerous cells, signs of early and late-stage cancer, whether it is slow or aggressive as well as genetic and hereditary risks in the patient.

-University of Oulu advances biosensor technology for disease detection

--The University of Oulu is at the forefront of developing cutting-edge biosensor technology that could revolutionize the early diagnosis and treatment of diseases.

-AI vs. dietitians: Can ChatGPT accurately assess your meals?

--Researchers evaluated ChatGPT-4’s accuracy in estimating nutrient content from meal images and found that while it correctly identified foods, it underestimated portion sizes and most nutrients, especially in larger meals.

-New deep learning method could revolutionize heart health monitoring

--Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon emission computed tomography (SPECT), uses a radioactive tracer and special camera to provide detailed images of blood flow to the heart, helping doctors detect coronary artery disease and other cardiovascular abnormalities.

-UVA launches trial to test AI-powered device for diabetes management

--For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge.

-Osaka University researchers develop innovative tool to study immune regulation

--Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for scientists. T cells, which are the frontline warriors in the battle against the infections, have been a major focus of research.

-Special zinc-based dissolvable material could transform treatment of broken bones

--Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates and screws typically used to hold fractured bones together.

-ChatGPT outperforms psychotherapists in therapy response ratings, study shows

--When it comes to comparing responses written by psychotherapists to those written by ChatGPT,the latter are generally rated higher, according to a study published February 12, 2025, in the open-access journal PLOS Mental Health by H. Dorian Hatch, from The Ohio State University and co-founder of Hatch Data and Mental Health, and colleagues.

-Takumi-shaped DNA hydrogels show promise for targeted therapies

--Hydrogels are polymeric materials with three-dimensional network structures containing large amounts of water. They serve as sustained-release drug delivery systems as they can encapsulate various bioactive substances, including drugs, antigens, and even cells.

-Digital health interventions fall short for patients with diabetes and heart disease

--Can telemedicine and exercise apps improve the health of people with type 2 diabetes and coronary heart disease? A large study led by the Technical University of Munich (TUM) shows that the positive effects are minimal.

-Spanish-language Android app created to help Hispanic smokers quit

--University of Houston researchers have created a first-of-its-kind, Spanish-language Android app called Impacto, designed specifically to help Hispanic smokers quit with guidance designed to reflect their cultural experiences.

-Atherosclerosis detection in lung cancer patients through CT scans

--Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at the time of the diagnosis and increase their risk of future heart disease, according to a new study being presented at ACC's Advancing the Cardiovascular Care of the Oncology Patient course.

-Study reveals low trust in health care system’s use of AI

--A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care systems to make sure an AI tool would not harm them.

-Biohybrid hand with muscle tissue mimics real-life movements

--A biohybrid hand which can move objects and do a scissor gesture has been built by a team at the University of Tokyo and Waseda University in Japan.